A DOUBLE-BLIND, PLACEBO-CONTROLLED CROSSOVER STUDY OF GANGLIOSIDE GM(1) TREATMENT FOR ALZHEIMERS-DISEASE

Authors
FLICKER C FERRIS SH KALKSTEIN D SERBY M
Citation
C. Flicker et al., A DOUBLE-BLIND, PLACEBO-CONTROLLED CROSSOVER STUDY OF GANGLIOSIDE GM(1) TREATMENT FOR ALZHEIMERS-DISEASE, The American journal of psychiatry, 151(1), 1994, pp. 126-129
Citations number
36
Categorie Soggetti
Psychiatry,Psychiatry
Journal title
The American journal of psychiatry → ACNP
ISSN journal
0002953X
Volume
151
Issue
1
Year of publication
1994
Pages
126 - 129
Database
ISI
SICI code
0002-953X(1994)151:1<126:ADPCSO>2.0.ZU;2-P
Abstract
In a double-blind trial, 12 patients with probable Alzheimer's disease were treated for 6 weeks with placebo and 6 weeks with monosialogangl ioside (GM(1)) (100 mg/day i.m.), which potentiates the actions of ner ve growth factor. GM(1) failed to produce significant improvement in p atients' cognitive test performance, suggesting that this is not a via ble approach to the treatment of cognitive deterioration in Alzheimer' s disease.